Cadrenal Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| – | -97.3% | -5.1% | +265.6% | |
| – | -29.8% | +99.8% | +36.7% | |
| – | – | – | – | |
| – | -34.8% | +1,198.1% | -170.0% | |
| – | +30.9% | +100.9% | -21.9% | |
| – | +30.9% | +100.9% | -21.9% | |
| – | – | – | – | |
| – | -118.6% | -100.0% | – | |
| – | +780.2% | -24.6% | -26.5% | |
| – | +25,586.4% | -80.7% | -472.0% | |
| – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.